I presume he was a troll deliberately trying to cause trouble which is a shame… |
Good area of support, here. Just a pulled back to it before next leg higher |
Done search but can’t see - can you post up link - cheers |
I answered your question with a genuine answer, have you watched the Share Soc presentation? |
francy-a clueless, serial deramper with new and ever changing handles across ADVFN. Just filter it. |
francois
Looking at your last post, I am now inclined not to give benefit of doubt and to concur with thiopia's sentiment.
Do one. |
Thanks Trout and LFD.
Bit naughty from THI.
Looking back at your posts you appear to be ok with yourself posting stuff about placings at companies, with some direct quotes from you below. Kettle , pot , black springs to mind .
“Everybody knows there is a bucket shop placing incoming right ?
Cash as of June 30th : £1m
Cash burn rate in H1 £0.8m
They must be running on fumes right now. Will have to do some sort of financing before results are issued”
And
“we've developed some amazing news technology but we can't tell you about it. Hmm you can smell the bucket shop placing from here.” |
As well as the cash grant, the FTI also allowed them use of the building, capital equipment and up to 20 staff that will be available to members of the FTI going forward.
This reduces costs dramatically and means they can do some higher margin work (using some of the available capital equipment).
The CEO was confirming the cash runway through to late this year before the FTI RNS. Have a look at the Share Soc presentation to hear for yourself. |
bit harsh thiopia (if a genuine query)
francois (giving benefit of doubt, but don't overdo it) - one of the many questions I had to make a call on, when I started building a position in December.
You presumably have taken into account improving sector sentiment and increasing FAB revenues. Also lower costs ( hugely supported by "free" expertise and resource at Queens) leading to higher margins on those increasing revenues.
My judgement was "yes" and that we are commencing a very exciting rerate. I now have a substantial position in FAB,
But all shares carry risk, and you must make your own judgement |
Genuine query . Looked at accounts to sept and cash balance low at £0.4m as per RNS statement. They have some debtors also at £0.4 , so £0.8m. Also got grant for £1m.
Fundamentals look good here but worry about cash position. Would possibly invest but even though CEO mentions no placing , can they be trusted. Sensible replies appreciated. Just doing due diligence and may have missed something. |
"cheeky bookmaking"...I think is a very generous description! |
Wouldn't let you buy in any size, I had orders rejected and others that only partial filled and were late printed. So they showed as sells, cheeky book making today. I imagine the price was deliberately driven down into that liquidity pool. Hopefully, we will see it recover just as fast now. |
To add to the above you can sell 500k at above the bid price. I cannot believe that there aren't more buyers down here... |
I was a bit sceptical about how serious the 3m+ was sitting on the the bid at 7.8p
Looking like a serious attempt now going on to fill it.
Some people may regret stop losses. |
 LFD... Most people selling, esp after the recent NCI news, did not read the RNS properly, and certainly do not understand the science. I though the update was good news, a couple (hopefully more) of potential targets the NCI identified and asking fusuion to do more work on them which could help validate the optimal platform as well. All it takes is one antibody to be identified (there is the potential for several over time using optimal and AI, and Fusion's own expertise) as being a possible drug candidate down the road. Maybe none from the NCI's pick will work, this need not be all down to optimal-they are fallible as well, but Fusion has a much wider pool to draw from and works with other candidates.
Unlike traditional chemo/pharma candidates the selection process, given the science available now, means that an antibody is much more likely to be specific to a particular antigen/target cell marker if it can cross the threshold in the lab, and is more likely to succeed as a drug candidate if entered into trials.
This is why you commonly see big pharma buying up micros with a lab validated antibody with good target specificity for hundreds of millions and then refining them and taking them on to clinical trials, where they are a more likely and safer bet then traditional chemicals to pass muster.
Fusion is not pharma. It is science, preclinical and does the heavy lifting big pharma lacks the exprtise and time in.
Obviously this is not cheap and companies like fusion, with it's ridiculous valuation, carry risks but given recent news and progress I feel it is on the right trajectory. Were it listed in the US, given their appetite for innovation, risk and much wider science based investor pool it would be multiples of it's current mrkt cap.
This is why we will never develop an Nvidia, Google or Amazon. These companies were given time in the US. |
Decent LinkedIn post today with two new videos on the optimal announcement!
linkedin.com/posts/fusion-antibodies-plc_fusion-antibodies-optimal-rd-update-activity-7292140273487220736-_xXs?utm_source=share&utm_medium=member_ios |
On the mails stock watch today |
I've been on too many bulletin boards where any share price reversal is agonised over by the bb disciples.
I remind myself that at any time there are scores, if not hundreds, of disconnected individuals who are making buy/sell/ hold decisions based on their individual circumstances and perception of prospects and risks.
So it is unlikely that there will be uniform (upward) share price trajectory.
What is a bit surprising though is that, on the day of what most would agree is a positive update on NCI progress, the share price ends lower.
Was there a sizeable number of holders who would have liked NCI progress to be "firmer" and also unsettled by the word "goodwill"?
Also my reading of the trades yesterday is that there was an element of artificiality most, if not all, of the day. With an inflated spread, the offer was held at 9p for long periods of time. The result was that many trades were recorded as sells, when in fact they were buys. My suspicion, but I can't prove it, is that buys probably exceeded sells over the day, but we ended up lower.
It's all too easy to shout "manipulation", but one does wonder what might be going on in the background. Added to all the scores/hundreds I mentioned above, there are also now probably much bigger players hovering in the background and bringing their influence on the share price
Their agendas might not be fully aligned with us mere pis.. |
thats some reversal today. Reason ? |
Excellent summary gtc
Might help inject some life into this thread. |
With the help of ChatGPT, a summary of why confirmation their optimal tech is working is a game changer
In my view this is why optimal is important and why today’s confirmation from Fab that NCI have been able to successfully use optimal is massive and not appreciated by market.
1. Faster Time-to-Market = Lower Costs & Higher ROI
• The average cost of developing a biologic drug exceeds $2B, with high attrition rates in late-stage trials.
• By reducing failure rates early, OptiMAL helps pharma companies de-risk investments, making Fusion Antibodies a high-value solution provider.
• A faster drug development cycle means more pharma partnerships, licensing opportunities, and recurring revenue for Fusion Antibodies.
2. Competitive Differentiation & Strategic Positioning
• OptiMAL uniquely supports small, highly targeted antibody libraries, making it a key enabler for next-generation biologics such as bispecifics, ADCs, and AI-designed antibodies.
• Competitors using traditional discovery methods face higher costs, longer timelines, and greater failure risks, giving Fusion Antibodies a strong competitive moat.
• Exclusive technologies like Mammalian Display allow the company to differentiate itself in a crowded market.
3. Strong Pharma & Biotech Industry Demand
• Pharma companies are outsourcing more R&D to specialist biotech firms with cutting-edge capabilities.
• Fusion Antibodies is well-positioned to become a go-to partner for both large pharmaceutical firms and emerging AI-driven biotech startups.
• High demand for faster, more predictive antibody discovery makes OptiMAL a critical asset in the industry.
Investment Takeaways
✅ Massive Market Opportunity: Taps into the rapidly growing biologics and AI-driven drug discovery space.
✅ Unique Technology & IP: Proprietary Mammalian Display and fully human antibody library provide strong differentiation.
✅ De-risking Biotech R&D: Helps pharma reduce failure rates, costs, and time-to-market.
✅ Scalability & Pharma Partnerships: Potential for recurring revenue, licensing deals, and strategic collaborations.
✅ Strong Market Tailwinds: Aligns with trends in AI-driven discovery, next-gen biologics, and digital R&D acceleration.
IMO Looks like Fusion Antibodies is quietly positioning itself to be a key player in the next era of antibody therapeutics, offering investors a compelling opportunity in a high-growth, high-demand market given its MCAP is only a reidculous £8m!! |
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Hot Features
Premium
